🔗 Share this article

Given that the United States continues making sweeping adjustments to its vaccination schedules, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by questioning coronavirus shots in the pandemic and has focused upon potential fatalities after Covid vaccination in her short tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Public health authorities had intended to reveal major revisions to the childhood immunization program earlier this month, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with many the world with insufficient data for public health gain. This reveal has been delayed until the new year.

Instead of Vinay Prasad, Høeg is scheduled to speak at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US in order to be more similar to the Danish model, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Background

Høeg has little discernible background in medication creation, approval processes or administrative roles, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Past heads of CBER would “understand legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who ran CBER have had.”

This division has an immense range of responsibilities at the agency, Woodcock emphasized.

“Everybody just focuses on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and more, and every single one must be supervised,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a major leadership element to the role, which supervises over 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” the former official concluded.

Official Statement and Contentious Programs

Regarding concerns about Dr. Høeg's fitness for the role and whether this selection represents greater collaboration among agency officials on immunizations, a representative stated that the “inquiries are based on inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her role,” the spokesperson explained, pointing to the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial one-day therapy clearance system that allegedly troubled her predecessors. “How are these drugs being picked for this voucher program? Who is making the choices?” Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards laxer regulations of pharmaceuticals, with the exception of shots.”

Established Past Work on Immunizations

With vaccines, Høeg has a more documented, if problematic, history, Howard observe. She published a analysis using non-validated volunteer-provided data to estimate the incidence of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the incoming government included revising regulations for recently developed shots and ending “optional” immunizations, she remarked following the vote on a online show. At the agency, Høeg has according to sources floated the idea of barring teenage boys from receiving Covid vaccinations.

“She’s an thorough ideologue who commences with her preconceived notions and works backwards to retrofit the data in a highly misleading, untruthful fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow dissenters, {like|